GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Rating) hit a new 52-week low on Wednesday . The company traded as low as $5.56 and last traded at $5.59, with a volume of 38409 shares. The stock had previously closed at $5.71.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on GDRX shares. Royal Bank of Canada upped their target price on GoodRx from $6.50 to $11.00 and gave the stock a “sector perform” rating in a research note on Tuesday, August 9th. The Goldman Sachs Group increased their price objective on GoodRx from $9.00 to $10.00 and gave the company a “neutral” rating in a research report on Tuesday, August 9th. Bank of America initiated coverage on GoodRx in a research report on Monday, June 6th. They set a “buy” rating and a $11.00 price objective on the stock. Credit Suisse Group increased their target price on GoodRx from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Tuesday, August 9th. Finally, Robert W. Baird dropped their target price on GoodRx from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, June 22nd. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $15.08.
GoodRx Trading Down 3.7 %
The company has a debt-to-equity ratio of 0.80, a current ratio of 11.23 and a quick ratio of 11.23. The company has a fifty day moving average price of $6.44 and a 200-day moving average price of $9.92.
Institutional Investors Weigh In On GoodRx
Several large investors have recently added to or reduced their stakes in GDRX. Qube Research & Technologies Ltd bought a new stake in GoodRx during the fourth quarter worth approximately $706,000. Bank of Montreal Can increased its stake in GoodRx by 108.0% during the fourth quarter. Bank of Montreal Can now owns 187,216 shares of the company’s stock worth $6,208,000 after acquiring an additional 97,221 shares during the last quarter. Rockefeller Capital Management L.P. increased its stake in GoodRx by 5.2% during the fourth quarter. Rockefeller Capital Management L.P. now owns 8,563 shares of the company’s stock worth $279,000 after acquiring an additional 421 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in GoodRx by 62.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,939,071 shares of the company’s stock worth $63,369,000 after acquiring an additional 742,906 shares during the last quarter. Finally, Ardmore Road Asset Management LP bought a new stake in GoodRx during the fourth quarter worth approximately $1,634,000. 39.16% of the stock is owned by institutional investors.
GoodRx Company Profile
GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.
- Get a free copy of the StockNews.com research report on GoodRx (GDRX)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.